CervoMed announces 32-week data from Extension phase of Phase 2b RewinD-LB

CervoMed (CRVO) announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial showing that oral neflamapimod continued to demonstrate slowing of disease progression and demonstrated an effect on a plasma marker of neurodegeneration in patients with DLB. The disease progression analyses were featured in two presentations during the Alzheimer’s Association International Congress 2025 on Sunday, July 27th, 2025. New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial: When evaluating clinically meaningful disease progression, patients treated with New Capsules demonstrated statistically significant slowed disease progression compared to patients treated with Old Capsules over 32 weeks. New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase: At Week 32 of the Extension phase, there was a statistically significant reduction from baseline in GFAP plasma levels in patients who received New Capsules for all 32 weeks, with a mean change of -18.4+/-4.0 pg/mL in all participants and -21.2+/-4.4 pg/mL in participants with screening plasma ptau181 below 2.2 pg/mL